Leukemia Research
Volume 27, Issue 7 , Pages 567-569 , July 2003

MDS—new classification, new problem?

Received 31 October 2002

References 

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982;51:189–199
  2. Albitar M, Beran M, O’Brien S, Kantarjian H, Frieriech E, Keating M, et al.  Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood. 2000;96:372–373
  3. List AF. New approaches to the treatment of myelodysplasia. Oncologist. 2002;7:39–49
  4. Bernstein SH, Brunettta VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, et al.  Acute myeloid leukemia-type therapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndromes as defined by French–American–British criteria Cancer and Leukemia Group B study. J. Clin. Oncol. 1996;14:2486–2494
  5. Estey E, Thaik P, Beran M, Kantarjian H, Pierce S, Keating M. Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969–2977
  6. Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, et al.  Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children’s Cancer Group. J. Clin. Oncol. 2002;20:434–444
  7. Germing U, Gatterman N, Strupp C, Aviado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes. Leuk. Res. 2000;24:983–992
  8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink, HK, Vardiman, J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. In: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. JCO; 1999. p. 3835–49.
  9. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, et al. Myelodyspalstic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon; 2001. p. 63–7.
  10. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, et al. Refractory anemia with excess blasts. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon; 2001. p. 71–3.
  11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  12. Strupp E, Galterman N, Giagounidis A, Aul C, Hildebrandt B, Haas R, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to WHO proposals. Leuk Res 2003;

    this issue.

  13. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of the myelodyspastic syndromes. Leuk Lymphoma. 1995;17:79–85
  14. Ohyashiki K, Nishimeki J, Shoji N, Miyazawa K, Kimuray Y, Ohyashiki JH. Re-evaluation of refractory anemia with excess blasts in transformation. Leuk. Res. 2001;25:933–939
  15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;9:2079–2088
  16. Cason J, Trujillo J, Estey E, Huh Y, Freireich EJ, Stass S. Peripheral acute leukemia. High peripheral but low marrow blast count. Blood. 1989;74:1758–1761
  17. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloonfield CD, et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–819
  18. Sanz GF, Sanz MA, Vallespi T, Canzio C, Torabadella M, Garcia S, et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395–408
  19. Aul C, Gatterman N, Heyll A, Germing U, Darigs G, Schnider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52–59
  20. Mufti J. A guide to risk assessment in the primary myelodysplastic syndromes. Hematol Oncol Clin North Am. 1992;6:587–606

PII: S0145-2126(02)00302-8

doi: 10.1016/S0145-2126(02)00302-8

Leukemia Research
Volume 27, Issue 7 , Pages 567-569 , July 2003

Article Tools